arrow
M

Michele Iuliani

university campus bio-medico
H指数:22
被引数:1,469

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Chemotherapy Backbone and Outcomes of Immune Checkpoint Inhibitor Combinations Across Solid Tumors: A Pan-Tumor Network Meta-Analysis

化疗基础方案与免疫检查点抑制剂联合疗法在实体瘤中的疗效:一项泛肿瘤网络Meta分析

2026-09-170
OAAI
Broad baseline-variable profiling of visceral conversion in bone-only HR+/ HER2-metastatic breast cancer treated with CDK4/6 inhibitors

骨转移性HR+/HER2-转移性乳腺癌经CDK4/6抑制剂治疗后腹腔转化的大范围基线-变量分析

2026-09-011
OA
Artificial intelligence for bone metastases: a systematic review and meta-analysis of diagnostic and prognostic performance

人工智能在骨转移中的应用:诊断和预后效能的系统评价与Meta分析

2026-08-300
OA
Comparative real-world Progression Free Survival of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Patients with Bone Metastases

CDK4/6抑制剂在HR+/HER2-骨转移性乳腺癌患者中的真实世界无进展生存比较

2026-05-010
OA
Denosumab is associated with longer Real-World Progression-Free Survival in BRCA1/2-Mutated HR+/HER2− breast cancer patients with bone metastases receiving CDK4/6 inhibitors: a multicenter Italian study

Denosumab与携带BRCA1/2突变的HR+/HER2−骨转移性乳腺癌患者接受CDK4/6抑制剂治疗时的真实世界无进展生存期延长相关:一项多中心意大利研究

2026-03-270
PRE
Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis

循环肿瘤DNA在早期乳腺癌中的预后意义:一项系统评价和荟萃分析

2026-02-230
PRE
Salivary microbial signature highlighting actinomyces as a predictor of immune-checkpoint inhibitor monotherapy response in advanced non–small cell lung cancer

唾液微生物特征突出放线菌作为晚期非小细胞肺癌免疫检查点抑制剂单药治疗反应的预测因子

2026-01-170
OAAI
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors

Denosumab与Zoledronic acid在接收CDK4/6抑制剂的晚期乳腺癌患者中的比较分析

2025-05-150
OA
S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models
2024-08-280
OAAI
MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness

MiR-662与早期乳腺癌的转移复发有关,并通过刺激癌细胞的干细胞来促进转移

2023-07-131
OAAI
Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis

接受免疫检查点抑制剂治疗的无骨转移患者骨转换标志物的变化: 一项探索性分析

2022-12-0115
OAAI